Wound Debridement Control Market Size is Projected to be USD 9.58 Billion by 2035; Industry is Propelling Owing to the Growing Technological Investments Globally

U. S. Wound Debridement Market is projected to grow from USD 1.70 Billion in 2025 to USD 2.96 Billion by 2035 owing to increased acceptance of debridement technologiesAustin, April 30, 2026 (GLOBE ...
Becker's Hospital Review

The value of early intervention with Collagenase SANTYL Ointment

A large-scale, real-world analysis of 15,639 patients treated with Collagenase SANTYL Ointment underscores the clinical and economic benefits of early enzymatic debridement in wound management. Using ...
USA Today

Chronic Non-Healing Wounds: Causes, Types & How Regenerative Treatments Can Help

Approximately 6.5 to 6.7 million people in the U.S. are affected by chronic wounds each year, and this number is expected to increase as the population ages. Poor blood circulation, high blood sugar ...
Nasdaq

MediWound Ltd. Publishes Post Hoc Analysis Comparing EscharEx® and Collagenase Ointment in Wounds Journal

MediWound Ltd. announced the publication of a peer-reviewed post hoc analysis in the journal Wounds, based on data from its Phase II ChronEx clinical trial for patients with venous leg ulcers (VLUs).
Taiwan News

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx ® in chronic wound care YAVNE, Israel, April 13, 2026 — MediWound ...